AdvaMed announced today that it created a comprehensive national COVID-19 diagnostic supply registry to aid state and federal pandemic responses.
According to a news release, AdvaMed is launching the registry in partnership with 13 commercial diagnostics manufacturers: Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), bioMérieux, Bio-Rad Laboratories (NYSE:BIO), Beckman Coulter, Cepheid, Hologic (NSDQ:HOLX), Ortho Clinical Diagnostics, Qiagen (NYSE:QGEN), Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers (ETR: SHL), and Thermo Fisher Scientific (NYSE:TMO).
The AdvaMed registry is designed to compile information from the diagnostic companies, along with public data, to create a centralized and standardized COVID-19 diagnostic supply registry to update on weekly numbers at state and national levels regarding molecular, antigen and serology tests shipped in the U.S.
AdvaMed said in the release that the registry will also help streamline communications and data sharing between the diagnostic companies and the multiple levels of governments, while also standardizing test supply reporting. It is also setting out to help laboratories and other public health stakeholders collaborate to optimize access to all platforms of COVID-19 testing.
More than 65 million tests have been manufactured and shipped across the U.S., with more than 800,000 test shipments daily, according to the registry’s first publicly released data set that ranges from the start of the pandemic.
“It is absolutely vital to our nation’s health and economic recovery that we have sufficient supplies to test everyone who needs it, and, just as important, to know where these supplies are so we can get them where they are most needed,” AdvaMed CEO Scott Whitaker said in the release. “This national registry will be a crucial tool for federal and state authorities as they work to protect both patients and health care providers and move to reopen the U.S. economy.
“We hope this registry serves as a key tool in our fight against COVID-19. We stand ready to partner with all providers, laboratories and other key stakeholders in the testing ecosystem to collaborate with the federal and state governments to coordinate efforts to support patient care and public health. Further, we stand ready to work with our partners in the federal government on any policies that would allow this registry to better serve patients and providers in need.”